Resveratrol Prevents Neuronal Apoptosis in an Early Brain Injury Model
Overview
Affiliations
Background: Resveratrol has been shown to attenuate cerebral vasospasm after subarachnoid hemorrhage (SAH); however, no study has explored its neuroprotective effect in early brain injury (EBI) after experimental SAH. The aim of this study was to evaluate the antiapoptotic function of resveratrol in EBI and its relationship with the PI3K/Akt survival pathway.
Methods: Experimental SAH was induced in adult male rats by prechiasmatic cistern injection. Control and SAH rats were divided into six groups and treated with low (20 mg/kg) or high (60 mg/kg) concentrations of resveratrol with or without LY294002 cotreatment. Brain samples of the rats were analyzed by immunohistochemistry, immunofluorescence staining, Western blotting, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assays.
Results: High-concentration but not low-concentration resveratrol treatment in SAH rats led to a significant increase in phosphorylated Akt (p-Akt) protein levels compared with SAH rats without treatment. In addition, p-Akt-positive cells mainly colocalized with NeuN-positive cells. Neuronal apoptosis in SAH rat brain was attenuated by high-concentration resveratrol treatment. The antiapoptotic effect of resveratrol in SAH rats could be partially abrogated by the PI3K/Akt signaling inhibitor LY294002.
Conclusions: Our results show that resveratrol has an antiapoptotic effect in EBI and that resveratrol might act through the PI3K/Akt signaling pathway.
Polyphenols Mediate Neuroprotection in Cerebral Ischemic Stroke-An Update.
Abdelsalam S, Renu K, Abu Zahra H, Abdallah B, Ali E, Veeraraghavan V Nutrients. 2023; 15(5).
PMID: 36904106 PMC: 10005012. DOI: 10.3390/nu15051107.
Zhang Z, Fang J, Zhou J, Ding F, Zhou G, Zhao X Oxid Med Cell Longev. 2022; 2022:3550204.
PMID: 36506933 PMC: 9729048. DOI: 10.1155/2022/3550204.
Antioxidant and neuroprotective actions of resveratrol in cerebrovascular diseases.
Wang Q, Yu Q, Wu M Front Pharmacol. 2022; 13:948889.
PMID: 36133823 PMC: 9483202. DOI: 10.3389/fphar.2022.948889.
Solar P, Zamani A, Lakatosova K, Joukal M Fluids Barriers CNS. 2022; 19(1):29.
PMID: 35410231 PMC: 8996682. DOI: 10.1186/s12987-022-00312-4.
Sun T, Duan L, Li J, Guo H, Xiong M Int J Mol Med. 2021; 48(2).
PMID: 34132355 PMC: 8208621. DOI: 10.3892/ijmm.2021.4979.